Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals, Inc. (TARS)
:TARS
TARS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.58 - $57.28
Previous CloseN/A
Volume127.14K
Average Volume (3M)563.07K
Market Cap
$1.73B
Enterprise Value$1.69B
Total Cash (Recent Filing)$407.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Nov 05, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding42,014,236
10 Day Avg. Volume591,107
30 Day Avg. Volume563,067
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue7.21
Enterprise Value/Gross Profit7.76
Enterprise Value/Ebitda-17.15
Forecast
1Y Price Target
$71.33Price Target Upside70.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTarsus Pharmaceuticals reported Q1 2025 revenues of $78.3M compared to $24.7M in the same period in 2024, indicating significant growth.
Market DemandA significant uptick in patients visiting the website, completing surveys, and using the 'find a doctor' tool is predictive of future demand for Xdemvy.
Product AdoptionThe ease of diagnosis and outstanding efficacy and safety profile of Xdemvy contributed to its rapid adoption among eye care professionals.
Bears Say
Market ChallengesManagement expressed confidence in continued growth in the Xdemvy launch despite upcoming summer headwinds.
Tarsus Pharmaceuticals News
TARS FAQ
What was Tarsus Pharmaceuticals, Inc.’s price range in the past 12 months?
Tarsus Pharmaceuticals, Inc. lowest stock price was $22.58 and its highest was $57.28 in the past 12 months.
What is Tarsus Pharmaceuticals, Inc.’s market cap?
Tarsus Pharmaceuticals, Inc.’s market cap is $1.73B.
When is Tarsus Pharmaceuticals, Inc.’s upcoming earnings report date?
Tarsus Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 89 days.
How were Tarsus Pharmaceuticals, Inc.’s earnings last quarter?
Tarsus Pharmaceuticals, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.379 by -$0.101.
Is Tarsus Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Tarsus Pharmaceuticals, Inc. pay dividends?
Tarsus Pharmaceuticals, Inc. does not currently pay dividends.
What is Tarsus Pharmaceuticals, Inc.’s EPS estimate?
Tarsus Pharmaceuticals, Inc.’s EPS estimate is -0.33.
How many shares outstanding does Tarsus Pharmaceuticals, Inc. have?
Tarsus Pharmaceuticals, Inc. has 42,014,236 shares outstanding.
What happened to Tarsus Pharmaceuticals, Inc.’s price movement after its last earnings report?
Tarsus Pharmaceuticals, Inc. reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.379. Following the earnings report the stock price went up 15.154%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in TARS
Tarsus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.33 (70.20% Upside)
$71.33 (70.20% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 541.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
79.94%
12-Months-Change
Fundamentals
Return on Equity
-31.46%
Trailing 12-Months
Asset Growth
43.37%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. (TARS) is a biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates to address unmet needs in ophthalmology and other therapeutic categories. The company is pioneering treatments for Demodex blepharitis, a common eyelid condition, with its lead product candidate, TP-03, which is designed to target and eradicate Demodex mites. Tarsus leverages its expertise in innovative chemistry and clinical development to create solutions that improve patient outcomes and address gaps in existing treatment options.
TARS Company Deck
TARS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance in sales and market penetration for XDEMVY, driven by successful DTC campaigns and prescriber engagement. However, the company faces challenges with high gross-to-net discounts and increased expenses. Despite these challenges, the momentum and growth potential of XDEMVY and future pipeline developments contribute to an overall optimistic outlook.View all TARS earnings summariesTARS Stock 12 Month Forecast
Average Price Target
$71.33
▲(70.20% Upside)
Technical Analysis
Ligand Pharma
―
Mirum Pharmaceuticals
―
Biohaven Ltd.
―
Apogee Therapeutics
―
Ascentage Pharma Group International Unsponsored ADR
―
Ownership Overview
3.34% Insiders
19.83% Mutual Funds
2.61% Other Institutional Investors
61.80% Public Companies and
Individual Investors